Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2010 Jun 1;16(12):1682–1692. doi: 10.1016/j.bbmt.2010.05.017

Table 1.

Patient, clinical, disease, and transplant characteristics of patients before and after HCT

a) Demographic and clinical factors at time of transplant

Variable N Distribution (%)

Patient Factors

Age 662
    Mean (SD), years 42.1 (11)
    Median (range), years 42.4 (18, 71)
    < 35 182 28%
    35–39 95 14%
    40–44 106 16%
    45–49 120 18%
    >50 159 24%

Gender
    Male 411 62%
    Female 251 38%

Race
    White 603 92%
    Other 56 8%

Marital status 655
    Married/living with partner/committed 493 75.3
    Other 162 24.7

Clinical Factors

Comorbid conditions (dichotomized as present or
not)
104 16%

Malignant disease at initial diagnosis, n (%)
    Acute leukemia (AML or ALL)
    Chronic leukemia (CML) 243 37%
    Breast cancer 131 20%
    Lymphoma (Hodgkin’s disease or non-
Hodgkin’s lymphoma)
156 24%
132 20%

Intensity of treatment before HCT
    Less intense 441 66.6
    More intense 221 33.4

Type of transplant
    Allogeneic 272 41.1
    Autologous 390 58.9

TBI in transplant conditioning regimen 235 35.5
b) Demographic and clinical factors after transplant at time of QOL interview

Variable N Distribution (%)

Patient Factors

Education 658
    High school or below 194 30
    Some college or technical education 209 32
    College degree (BA/BS) 122 18
    Education beyond bachelor’s degree 133 20

Marital status 659
    Married/living with partner/committed 483 73
    Other 176 27

Occupational status
    Retired 75 11
    Not working 100 15
    Working or student 484 73

Family income
    <$20,000 70 11
    $20,000–40,000 141 22
    $40,000–60,000 156 24
    $60,000–80,000 100 15
    >$80,000 181 28

Insurance status 597
    Public 193 32
    Private 387 65
    No insurance 17 3

Clinical Factors

Comorbid conditions 104 16%

Severity of transplant experience
    Low severity (autologous) 390 60
    Intermediate severity (allogeneic without
chronic GVHD)
168 26
    High severity (allogeneic with chronic GVHD) 88 14

Time since transplant, in years, median, (standard
deviation) (mean)
662 6.6 (3.1) (7.0)

Distance between transplant center and residence
(in miles) (standard deviation)
600 148 (317)

Acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), total body irradiation (TBI)